Safety Profile
Ref: www.entrestohcp.com
The most commonly reported adverse reactions during treatment with...
Ref: www.entrestohcp.com
The most commonly reported adverse reactions during treatment with...
Entresto is reimbursed for the treatment of adult patients with chronic heart failure with reduced ejection fraction in Belgium.
This treatment is reimbursed for patients:
NYHA Class II/III/IV Left Ventricular Ejection Fraction ≤ 35% (...Sacubitril/valsartan, a first-in-class ARNI, delivers simultaneous inhibition of neprilysin and blockade of the AT1 receptor. Sacubitril/valsartan is a sodium salt complex comprising sacubitril (AHU377), a prodrug, which is further metabolized to the...
Ref: www.entrestohcp.com
The efficacy of ENTRESTO has been investigated through...
Together for Better In the fight against heart failure condition, we work our hardest every day to develop innovative and effective medication to sustain a better life, keeping the patient in mind. We are aware that the result of...
PARADIGM-HF is the largest study to date in heart failure patients. 1
Summary:
The PARADIGM-HF study on systolic heart failure with 8,399 patients in NYHA class II-IV. 2,3...
The recently presented PIONEER-HF studies the efficacy and safety of initiating ENTRESTO compared to enalapril prior to discharge after hospitalization for an acute decompensated heart failure episode. 1 The results of PIONEER-HF...
In de afgelopen 10 jaar heeft het behandelingslandschap van SpA een substantiële verandering ondergaan, met een uitbreiding van nieuwe therapieën en nieuwe werkingsmechanismen. Er zijn richtlijnen en...